* All proposals of Board of Directors approved

  * Gilbert Ghostine re-elected as Chairman of Board of Directors; all other
    Board members standing for election confirmed

* Mathai Mammen, Graeme Pitkethly and Michael Rechsteiner elected as new Board

    members
  * Dividend of CHF 0.45 per registered dividend-paying share approved,
    representing 24% of core net income

Basel, April 30, 2024 - Sandoz (SIX: SDZ; OTCQX: SDZNY) today announced that its
shareholders approved all proposals of the Board of Directors at its Annual
General Meeting, including the Annual Financial Statements and Consolidated
Financial Statements as well as the report on non-financial matters for the
2023 financial year. The shareholders in attendance, together with the votes
represented by the independent proxy, represented 79.23% of registered shares.
Gilbert Ghostine, who was confirmed as Chairman of the Board of Directors,
addressed shareholders in a speech today: "I would like to thank you for joining
us on this journey - and give my sincere thanks for the trust you have placed in
us and in Sandoz. We are very proud of what has been achieved so far and we are
excited about the potential for our continued success in the future. These
achievements would not have been attained without the individual and collective
contributions of all our colleagues at Sandoz."
In addition, shareholders approved the proposed appropriation of available
earnings and the dividend of 0.45 Swiss francs per registered dividend-paying
share, representing 24% of core net income. The dividend will be paid, subject
to deduction of Swiss withholding tax, as of May 7, 2024. The last trading day
with entitlement to receive the dividend is May 2, 2024.
In two separate votes, shareholders approved the maximum aggregate amount of
compensation for the Board of Directors for the period until the next Annual
General Meeting, and the maximum aggregate amount of compensation for the
members of the Executive Committee for the 2025 financial year. Shareholders
also endorsed the 2023 Compensation Report in an advisory vote.
In addition to the re-election of Gilbert Ghostine as Chairman, shareholders
also elected all other members of the Board of Directors who stood for re-
election for a one-year term:

  * Karen J. Huebscher, Ph.D.
  * Urs Riedener
  * Shamiram R. Feinglass, M.D.
  * Aarti Shah, Ph.D.
  * Ioannis Skoufalos
  * Maria Varsellona

Mathai Mammen, M.D., Ph.D., Graeme Pitkethly and Michael Rechsteiner were
elected as new members of the Board of Directors for a term of one year.
The following Board members were elected to the Human Capital and ESG Committee
for a term of one year:

  * Urs Riedener
  * Michael Rechsteiner
  * Aarti Shah, Ph.D.
  * Ioannis Skoufalos
  * Maria Varsellona

The Board of Directors intends to redesignate Urs Riedener as chair of the Human
Capital and ESG Committee.
The Annual General Meeting also re-elected KPMG AG as statutory auditors for the
2024 financial year and Advoro Zurich AG as independent proxy until the
conclusion of the 2025 Annual General Meeting.
For a detailed listing of all resolutions at the 2024 Annual General Meeting,
please visit: https://www.sandoz.com/agm/
Disclaimer
This Media Release contains forward-looking statements, which offer no guarantee
with regard to future performance. These statements are made on the basis of
management's views and assumptions regarding future events and business
performance at the time the statements are made. They are subject to risks and
uncertainties including, but not confined to, future global economic conditions,
exchange rates, legal provisions, market conditions, activities by competitors
and other factors outside of the control of Sandoz. Should one or more of these
risks or uncertainties materialize or should underlying assumptions prove
incorrect, actual outcomes may vary materially from those forecasted or
expected. Each forward-looking statement speaks only as of the date of the
particular statement, and Sandoz undertakes no obligation to publicly update or
revise any forward-looking statements, except as required by law.
About Sandoz
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar
medicines, with a growth strategy driven by its Purpose: pioneering access for
patients. 20,000 people of more than 100 nationalities work together to bring
Sandoz medicines to some 800 million patients annually worldwide, generating
substantial global healthcare savings and an even larger total social impact.
Its leading portfolio of 1,500 products addresses diseases from the common cold
to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back
to the year 1886. Its history of breakthroughs includes Calcium Sandoz in 1929,
the world's first oral penicillin in 1951, and the first biosimilar in 2006. In
2023, Sandoz achieved sales of USD 9.6 billion and core EBITDA of USD 1.9
billion.
CONTACTS
-------------------------------------------------------------------
Global Media Relations contacts Investor Relations contacts
-------------------------------------------------------------------
Global.MediaRelations@sandoz.com Investor.Relations@sandoz.com
-------------------------------------------------------------------

  Joerg E. Allgaeuer                 Karen M. King
  +49 171 838 4838                   +1 609 722 0982

-------------------------------------------------------------------

  Chris Lewis                        Laurent de Weck
  +49 174 244 9501                   +41 61 529 14 85

-------------------------------------------------------------------Â